Skip to content
    Clinical Trials

    Teclistamab With Daratumumab Linked to Better PFS and OS vs Standard PI Regimens

    Anderson et alAdvances in Therapy

    Teclistamab With Daratumumab Linked to Better PFS and OS vs Standard PI Regimens
    In the phase 3 MajesTEC-3 trial (NCT05083169), teclistamab combined with daratumumab (Tec-Dara) significantly improved progression-free survival (PFS) and overall survival (OS) compared to investigator's choice of daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) after 1 to 3 prior lines of therapy. Among comparator-arm patients, 85.5% (253/296) were refractory to an immunomodulatory drug (IMiD); 90.7% (263/290) received IMiD-based DPd and 9.3% (27/290) received proteasome inhibitor (PI)-based DVd.
    To evaluate Tec-Dara against standard PI-based combinations, researchers conducted an inverse probability of treatment weighting (IPTW) analysis utilizing individual patient-level data from MajesTEC-3, the CANDOR trial (NCT03158688; daratumumab/carfilzomib/dexamethasone [DKd]), and the CASTOR trial (NCT02136134; DVd). Following weighting adjustment, baseline patient characteristics were well balanced across the study cohorts.
    Tec-Dara was significantly associated with prolonged PFS compared with DKd (HR 0.22; 95% CI 0.15–0.33; P < 0.001) and DVd (HR 0.11; 95% CI 0.07–0.17; P < 0.001). Tec-Dara was also significantly associated with prolonged OS versus DKd (HR 0.40; 95% CI 0.26–0.61; P < 0.001) and DVd (HR 0.24; 95% CI 0.14–0.40; P < 0.001). Additionally, patients demonstrated higher overall response rates (ORR RR 1.11 vs DKd; RR 1.10 vs DVd), very good partial response or better (≥VGPR RR 1.33 vs DKd; RR 2.20 vs DVd), and complete response or better (≥CR RR 2.84 vs DKd; RR 5.17 vs DVd). The authors conclude these results demonstrate consistent survival benefits and deeper responses, supporting Tec-Dara as a new standard-of-care regimen for RRMM as early as the second line.

    Key Takeaways

    • Tec-Dara was significantly associated with reduced risk of progression or death compared with DKd (HR 0.22; 95% CI 0.15–0.33; P < 0.001) and DVd (HR 0.11; 95% CI 0.07–0.17; P < 0.001).
    • Overall survival was significantly improved with Tec-Dara compared with DKd (HR 0.40; 95% CI 0.26–0.61; P < 0.001) and DVd (HR 0.24; 95% CI 0.14–0.40; P < 0.001).
    • Patients receiving Tec-Dara achieved higher complete response or better rates compared with DKd (RR 2.84) and DVd (RR 5.17).
    Read the original sourceAdvances in Therapy